Mast cell stabilizers for treatment of hypercytokinemia and viral infection
Inventors
Hyde-Deruyscher, Robin Parish • Hyde-DeRuyscher, Nancy Harlan • Hyde-DeRuyscher, Elicia Kristine
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention relates to methods for treating or ameliorating hypercytokinemia and viral infections associated with hypercytokinemia using norketotifen or a pharmaceutically acceptable salt thereof, optionally in combination with an antiviral agent.
Core Innovation
The described invention treats or ameliorates hypercytokinemia caused by a virus infection by administering norketotifen or a pharmaceutically acceptable salt thereof. It also describes treating or ameliorating a virus infection associated with hypercytokinemia using norketotifen or a pharmaceutically acceptable salt. The treatment reduces excessive inflammatory mediator release while preserving adaptive pathogen clearance.
The description also provides for combining norketotifen with an antiviral agent or another therapeutic agent, and for use with physical treatment. The problem addressed in the available text is excessive inflammatory mediator release associated with viral infection. The description further compares predicted ketotifen serum levels for different dosing regimens, including a time-release dosage form.
Claims Coverage
The two independent claims cover two inventive features: treatment or amelioration of virus-caused hypercytokinemia, and treatment or amelioration of a virus infection associated with hypercytokinemia.
Treating virus-caused hypercytokinemia
Independent claim 1 covers treating or ameliorating hypercytokinemia caused by a virus infection by administering a therapeutically effective amount of norketotifen or a pharmaceutically acceptable salt thereof.
Treating a virus infection associated with hypercytokinemia
Independent claim 9 covers treating or ameliorating a virus infection associated with hypercytokinemia by administering a therapeutically effective amount of norketotifen or a pharmaceutically acceptable salt thereof.
The independent claims distinguish treatment of virus-caused hypercytokinemia from treatment of a virus infection associated with hypercytokinemia. Both specify administration of norketotifen or a pharmaceutically acceptable salt thereof.
Stated Advantages
The described treatment reduces excessive inflammatory mediator release while preserving adaptive pathogen clearance.
Documented Applications
Treatment or amelioration of hypercytokinemia caused by a virus infection, including the respiratory virus and norovirus infection categories specified in dependent claims.
Treatment or amelioration of a virus infection associated with hypercytokinemia, including respiratory virus infection and norovirus infection.
Interested in licensing this patent?